Effects of AR-L 115 BS on hemodynamics and contractility of the heart in cardiac patients.
During diagnostic heart catheterization and/or coronary angiography 25 patients with coronary heart disease(21 pts), congestive cardiomyopathy (3) and aortic valve incompetence (1) were examined in two studies: 7 patients received 150 mg 2-[(2-methoxy-4-methylsulfinyl)phenyl]-1H-imidazol[4,5-b]pyridine (AR-L 115 BS) orally. The hemodynamic parameters were recorded for 1 h. There was a significant increase in heart rate and dp/dt max and a decrease in stroke volume. There was no significant change in cardiac output. Left ventricular diastolic pressure was reduced, but was statistically not significant. 18 patients received 0.7 mg/kg AR-L 115 BS by injection into the pulmonary artery after control ventriculography of the left ventricle. Ventriculography was repeated 10-12 min later. Acute hemodynamic changes comprised a significant increase in heart rate and cardiac output, and a significant decrease in LVEDP, pulmonary artery mean pressure and LV systolic pressure. The ejection fraction was not consistently improved but showed a definite increase in patients with myocardial ischemia at rest and in patients with cardiomyopathy. An acute antianginal effect was observed in two cases and explained by a marked peripheral vasodilation.
D002302:Cardiac Output / Q000187:drug effects; D002316:Cardiotonic Agents / Q000494:pharmacology*; D005260:Female; D006331:Heart Diseases / Q000503:physiopathology*; D006339:Heart Rate / Q000187:drug effects; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology*; D008297:Male; D008875:Middle Aged; D009200:Myocardial Contraction / Q000187:drug effects*; D013318:Stroke Volume / Q000187:drug effects; D013997:Time Factors
D002316:Cardiotonic Agents; D007093:Imidazoles; C029758:sulmazole